Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterVentional Technologies

This article was originally published in The Gray Sheet

Executive Summary

Firm enrolls first of 1,244 patients in a randomized controlled study comparing restenosis rates of its Barath surgical dilatation balloon catheter and conventional percutaneous transluminal coronary angioplasty. The cutting balloon "combines a conventional angioplasty balloon with microsurgical blades" that "incise the lesion ahead of the expanding balloon." Animal studies indicate that the combination will "facilitate maximal dilatation of the artery and lesion with the least amount of dilating force, which minimizes trauma to the artery." The investigational device exemption allows for 20 centers; 15 are expected to "come on line" by the middle of August
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002582

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel